Rigel Pharmaceuticals Inc
RIGL Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$49.91
KIRA · Stoqly’s AI analyst, in plain words
- Rigel Pharmaceuticals Inc had $294M of revenue in fiscal 2025, up 64.1% on the year before. Over five years, revenue changed +22.1% a year on average.
- Its operating margin was 42.6%, up 29.1 pts: of every 100 in sales, about 43 is left after running the business.
- Rigel Pharmaceuticals Inc made $367M of net profit in fiscal 2025.
- Rigel Pharmaceuticals Inc has $102M more cash than debt.
Market cap
$977M
P/E
3.0x
Revenue
$294M
Net income
$367M
Free cash flow
—
Operating margin
42.6%
Rigel Pharmaceuticals Inc in 30 seconds · fiscal 2025
Are sales growing?
+64.1%
Yes. Sales grew 64.1% last year.
Does it make a profit?
124.7%
Yes. It keeps 124.7% of every sale as profit.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
3.0x
One share costs 3.0 times its yearly profit per share.
What Rigel Pharmaceuticals Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- RIGEL PHARMACEUTICALS INC
- CIK
- 0001034842
Rigel Pharmaceuticals Inc · RIGL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $149M | $120M | $117M | $179M | $294M |
| Revenue growth | 37.4% | −19.4% | −2.8% | 53.4% | 64.1% |
| Gross margin | 99.3% | 98.5% | 93.9% | 89.6% | 93.3% |
| Operating margin | −8.4% | −46.2% | −17.5% | 13.5% | 42.6% |
| Net income | −$17.9M | −$58.6M | −$25.1M | $17.5M | $367M |
| Net margin | −12.0% | −48.7% | −21.5% | 9.8% | 124.7% |
| Diluted EPS | −$0.11 | −$3.44 | −$1.44 | $0.99 | $19.48 |
| Cash | |||||
| Cash from operations | $5.9M | −$73.8M | −$5.7M | $31.5M | $75.7M |
| Capital expenditure | $0.6M | $0.5M | — | — | — |
| Free cash flow | $5.3M | −$74.2M | — | — | — |
| FCF margin | 3.5% | −61.7% | — | — | — |
| Share count change | 1.0% | −90.0% | 2.1% | 1.6% | 6.5% |
| Debt and strength | |||||
| Cash and short-term investments | $125M | $58.2M | $56.9M | $77.3M | $155M |
| Debt incl. finance leases | $20.0M | $40.0M | $60.0M | $60.0M | $52.5M |
| Shareholders' equity | $30.4M | −$13.6M | −$28.6M | $3.3M | $391M |
| Net debt / EBITDA | — | — | — | −0.7x | −0.8x |
| Current ratio | 2.4x | 1.8x | 1.9x | 2.1x | 2.4x |
| Interest coverage | −2.6x | −15.0x | −3.0x | 3.1x | 17.1x |
| Returns and quality | |||||
| Return on capital | — | — | — | — | 43.4% |
| Return on equity | −55.6% | −699.0% | — | — | 185.9% |
| Return on tangible equity | −59.0% | — | — | — | 100.1% |
| Piotroski F-score | 6 | 2 | 4 | 7 | 6 |
| Altman Z'' | −22.5 | −34.0 | −38.0 | −23.8 | 0.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.3M
2 insiders
Of sales under plans
52%
$0.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Rigel Pharmaceuticals Inc · RIGL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $49.91 a share, the company is worth $977M: 3.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001034842). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.